Dr. Haim Barr completed his Ph.D. studies in the Technion – Israel Institute of Technology in 2001 and then pursued a career in biotechnology for 11 years. Coming from academic studies in the fields of ubiquitin and phosphatase biology, Haim initially was a research group leader and then lead drug discovery efforts in Proteologics Ltd. In those years, Proteologics successfully transferred from target to small molecule discovery with a unique and automated integration of in vitro ubiquitination assays which has become the backbone of the company’s activities. Subsequently, Haim joined BiolineRx Ltd. where he specialized in recruitment and management of early-phase projects from Israeli and international academic labs for translation into industrial/clinical development. In addition to Haim’s basic science and automation skills, he has been involved in bio-industrial business development for several years, where he served as in-licensing manager in BiolineRx.